AIM: Cationic ethylphosphatidylcholines (ePCs) were evaluated for the delivery of siRNA in modified breast cancer cells. MATERIALS AND METHODS: Dimyristoleoyl-ePC (C14), dioleoyl-ePC (C18), and dilauroyl-ePC (C12) nanoparticles were complexed with siRNA for green fluorescent protein (GFP) suppression in modified MCF-7 breast cancer cells. The kinetics of GFP suppression were followed over the course of 72 hours. RESULTS: C14, which has been previously found to be particularly effective in gene transfection into primary human umbilical artery endothelial cells, was also remarkably effective as siRNA carrier, with an efficacy exceeding that of Lipofectamine RNAiMAX. The C14 toxicity remained comparable to that of RNAiMAX. The efficacy of the other tested cationic ePC formulations was less than that of C14 and RNAiMAX. CONCLUSION: The cationic lipid C14 is a highly efficient siRNA carrier that could be used for the development of new formulations for siRNA delivery into cancer cells. A valuable advantage of the C14 formulations is the fact that they are simple, and do not require adjuvants or complex preparation procedures.
AIM: Cationic ethylphosphatidylcholines (ePCs) were evaluated for the delivery of siRNA in modified breast cancer cells. MATERIALS AND METHODS:Dimyristoleoyl-ePC (C14), dioleoyl-ePC (C18), and dilauroyl-ePC (C12) nanoparticles were complexed with siRNA for green fluorescent protein (GFP) suppression in modified MCF-7breast cancer cells. The kinetics of GFP suppression were followed over the course of 72 hours. RESULTS: C14, which has been previously found to be particularly effective in gene transfection into primary human umbilical artery endothelial cells, was also remarkably effective as siRNA carrier, with an efficacy exceeding that of Lipofectamine RNAiMAX. The C14 toxicity remained comparable to that of RNAiMAX. The efficacy of the other tested cationic ePC formulations was less than that of C14 and RNAiMAX. CONCLUSION: The cationic lipid C14 is a highly efficient siRNA carrier that could be used for the development of new formulations for siRNA delivery into cancer cells. A valuable advantage of the C14 formulations is the fact that they are simple, and do not require adjuvants or complex preparation procedures.
Authors: P G Noone; K W Hohneker; Z Zhou; L G Johnson; C Foy; C Gipson; K Jones; T L Noah; M W Leigh; C Schwartzbach; J Efthimiou; R Pearlman; R C Boucher; M R Knowles Journal: Mol Ther Date: 2000-01 Impact factor: 11.454
Authors: Kevin T Love; Kerry P Mahon; Christopher G Levins; Kathryn A Whitehead; William Querbes; J Robert Dorkin; June Qin; William Cantley; Liu Liang Qin; Timothy Racie; Maria Frank-Kamenetsky; Ka Ning Yip; Rene Alvarez; Dinah W Y Sah; Antonin de Fougerolles; Kevin Fitzgerald; Victor Koteliansky; Akin Akinc; Robert Langer; Daniel G Anderson Journal: Proc Natl Acad Sci U S A Date: 2010-01-11 Impact factor: 11.205
Authors: R C MacDonald; G W Ashley; M M Shida; V A Rakhmanova; Y S Tarahovsky; D P Pantazatos; M T Kennedy; E V Pozharski; K A Baker; R D Jones; H S Rosenzweig; K L Choi; R Qiu; T J McIntosh Journal: Biophys J Date: 1999-11 Impact factor: 4.033
Authors: Sean C Semple; Akin Akinc; Jianxin Chen; Ammen P Sandhu; Barbara L Mui; Connie K Cho; Dinah W Y Sah; Derrick Stebbing; Erin J Crosley; Ed Yaworski; Ismail M Hafez; J Robert Dorkin; June Qin; Kieu Lam; Kallanthottathil G Rajeev; Kim F Wong; Lloyd B Jeffs; Lubomir Nechev; Merete L Eisenhardt; Muthusamy Jayaraman; Mikameh Kazem; Martin A Maier; Masuna Srinivasulu; Michael J Weinstein; Qingmin Chen; Rene Alvarez; Scott A Barros; Soma De; Sandra K Klimuk; Todd Borland; Verbena Kosovrasti; William L Cantley; Ying K Tam; Muthiah Manoharan; Marco A Ciufolini; Mark A Tracy; Antonin de Fougerolles; Ian MacLachlan; Pieter R Cullis; Thomas D Madden; Michael J Hope Journal: Nat Biotechnol Date: 2010-01-17 Impact factor: 54.908